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Background
Disabling pansclerotic morphea is an extremely rare and
severe disorder in children, systemic treatment with cor-
ticosteroids and methotrexate (MTX) or mycophenolate
mofetil (MMF) are the most common therapies. How-
ever, patients can develop severe disabilities. Autologous
stem cell transplantion (ASCT) is a successful treatment
option for systemic scleroderma and might also be ben-
eficial for severe therapy resistant disabling pansclerotic
morphea.
Aim
To report about two children with severe disabling mor-
phea, who received ASCT.
Methods
Two children were diagnosed at the age of six years
with disabling pansclerotic morphea of the right (patient
1, male) and left (patient 2, female) leg and trunk,
respectively. In spite of therapy with PUVA, pulsed
methylprednisolone, MTX and MMF (patient 1) disease
progression was rapid in both children. ASCT was per-
formed using a CD3/CD19-depleted graft after immu-
noablative conditioning with fludarabine,
cyclophosphamide and anti-thymocyte globuline at 16
months (patient 1) and 11 months (patient 2) after
initial diagnosis.
Patients and results
Progressions of disabling morphea was halted in both
children. The skin softened and the leg function
improved and no immunosuppressive therapy was
needed , after uneventful ASCT. However, at 18 months
following ASCT, patient 1 developed new cutaneus but
no deep or disabling lesions and glucocorticoid and
MTX treatment was restarted. At 12 months following
ASCT, patient 2 developed new cutaneus, osseus, cere-
bral and renal lesions. She received MTX and corticos-
teroids for 4 months until her parents refused further
therapy.
Conclusions
ASCT can stop the rapid progress of the disabling
lesions in children with disabling morphea. However
new skin lesions and other related lesions may reoccur.
It remains unclear, if immunosuppressive therapy imme-
diatedly following ASCT could have induced persistent
remission.
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